RxDoctor Payments Data

Michelle Lisgaris, MD

Infectious Disease · Cleveland, OHNPI 1881614576

Payments from drug & device makers

$4,146in general payments, 2019–2025

Across 185 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$855
  • Johnson & Johnson$824
  • Janssen Products, LP$565
  • Merck$437
  • Insmed, Inc.$303
  • Melinta Therapeutics, LLC$268
  • plus $891 from 12 others

What the payments were for

  • Speaking & faculty fees$160%
  • Food & beverage$3,83392%
  • Education$2977%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,146 in reported general payments places this provider in the 75th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$27,473
Medicare patients
128
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf113$559,237
BiktarvyBictegrav/Emtricit/Tenofov Ala58$240,240
TivicayDolutegravir Sodium98$219,837
GenvoyaElviteg/Cob/Emtri/Tenof Alafen48$185,236
ArikayceAmikacin Liposomal/Neb.Accessr12$184,066
TriumeqAbacavir/Dolutegravir/Lamivudi41$151,376
DescovyEmtricitabine/Tenofov Alafenam58$121,433
PrezcobixDarunavir/Cobicistat46$111,100
StribildElviteg/Cob/Emtri/Tenofo Disop24$98,001
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$54,608
PifeltroDoravirine14$27,847
IsentressRaltegravir Potassium13$25,510
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df49$11,095
AbacavirAbacavir Sulfate23$5,157
Vancomycin Hcl28$3,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Stribild$855$644,910188 claims
Janssen Products, LPSymtuza$565$559,237113 claims
Viiv Healthcare CompanyTivicay, Triumeq$118$371,214139 claims
Insmed, Inc.Arikayce$303$184,06612 claims
Johnson & JohnsonPrezcobix$824$111,10046 claims
MerckPifeltro, Isentress$437$53,35727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →